U.S. Markets close in 2 hrs 19 mins
  • S&P 500

    4,142.74
    -2.45 (-0.06%)
     
  • Dow 30

    32,840.49
    +37.02 (+0.11%)
     
  • Nasdaq

    12,651.39
    -6.17 (-0.05%)
     
  • Russell 2000

    1,937.32
    +15.50 (+0.81%)
     
  • Crude Oil

    89.91
    +0.90 (+1.01%)
     
  • Gold

    1,805.50
    +14.30 (+0.80%)
     
  • Silver

    20.60
    +0.76 (+3.82%)
     
  • EUR/USD

    1.0203
    +0.0016 (+0.15%)
     
  • 10-Yr Bond

    2.7680
    -0.0720 (-2.54%)
     
  • GBP/USD

    1.2082
    +0.0011 (+0.09%)
     
  • USD/JPY

    134.7030
    -0.2670 (-0.20%)
     
  • BTC-USD

    23,948.30
    +709.89 (+3.05%)
     
  • CMC Crypto 200

    557.99
    +15.12 (+2.78%)
     
  • FTSE 100

    7,482.37
    +42.63 (+0.57%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

So should Lyell Immunopharma (NASDAQ:LYEL) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Check out our latest analysis for Lyell Immunopharma

When Might Lyell Immunopharma Run Out Of Money?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Lyell Immunopharma last reported its balance sheet in March 2022, it had zero debt and cash worth US$614m. Importantly, its cash burn was US$197m over the trailing twelve months. Therefore, from March 2022 it had 3.1 years of cash runway. A runway of this length affords the company the time and space it needs to develop the business. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Well Is Lyell Immunopharma Growing?

Lyell Immunopharma reduced its cash burn by 16% during the last year, which points to some degree of discipline. Unfortunately, however, operating revenue declined by 2.1% during the period. In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Can Lyell Immunopharma Raise More Cash Easily?

There's no doubt Lyell Immunopharma seems to be in a fairly good position, when it comes to managing its cash burn, but even if it's only hypothetical, it's always worth asking how easily it could raise more money to fund growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Lyell Immunopharma has a market capitalisation of US$1.5b and burnt through US$197m last year, which is 14% of the company's market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is Lyell Immunopharma's Cash Burn Situation?

On this analysis of Lyell Immunopharma's cash burn, we think its cash runway was reassuring, while its falling revenue has us a bit worried. Considering all the factors discussed in this article, we're not overly concerned about the company's cash burn, although we do think shareholders should keep an eye on how it develops. On another note, Lyell Immunopharma has 4 warning signs (and 1 which is potentially serious) we think you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here